As the ACR’s megaphone, the Communications and Marketing Committee helps get clear and accurate information into the hands of those who need it, whether that’s clinicians, researchers, educators or patients, says chair Howard Yang, MD, RhMSUS.
Articles by From the College
RheumPAC First Quarter Fundraising Update
First-quarter donations have put RheumPAC in great shape to help build a Congress that supports the needs of the rheumatology community. Consider joining your colleagues today in support of the ACR’s Congressional champions.
Looking Ahead to Advocates for Arthritis 2025
This May, more than 120 ACR leaders, fellows and patients with rheumatic disease will converge in Washington, D.C., to lobby Congress on issues including protecting Medicare and Medicaid, National Institutes of Health research funding and pharmacy benefit manager reform.
A ‘Polarized’ Topic: Synovial Fluid Crystal Examinations
Answer a short survey to help the ACR’s Committee on Rheumatologic Care decide whether the ACR should seek CMS approval for synovial fluid crystal analysis as a provider-performed microscopy procedure.
State Legislative Update, Spring 2025
With the state legislative session in full swing, the ACR is currently tracking 114 pieces of state legislation across many issue areas, including utilization management, prescription drug review boards and vaccines.
CMS Nominee Mehmet Oz’s Stated Policy Priorities & Rheumatology
With Mehmet Oz, MD, expected to be confirmed as administrator of the Centers for Medicare & Medicaid Services, the ACR considers how his stated priorities may affect rheumatology.
ACR Commends the Introduction of Legislation to Support the Medical Workforce
Three bills centering reintroduced in the 119th Congress would ease educational debt burden, increase placement access for visa holders and support the mental health of current healthcare workers.
March Updates from the ACR Insurance Subcommittee
The Insurance Subcommittee is working on behalf of ACR members to address underwater formulary requirements for biosimilars, mandated switches to biosimilars, evaluation and management downcoding and more.
HHS Policy Shift Raises Questions about Future of Public Comment on Rulemaking
The rescindment of the Richardson Waiver in late February suggests that the HHS may move toward rulemaking without providing public notice and comment procedures.
How NIH, FDA Nominees May Affect Rheumatology
The nominations of Jay Bhattacharya, MD, PhD, as director of the National Institutes of Health and Martin Makary, MD, MPH, for commissioner of the Food & Drug Administration have the potential to significantly impact federally funded healthcare research, federal responses to public health emergencies and federal regulation of drugs and medical devices.
- 1
- 2
- 3
- …
- 94
- Next Page »